Paradoxical reversal of Hsp90 inhibitor-induced BCR-ABL degradation by the BCR-ABL inhibitor

被引：0
|
作者：
Tsukahara, F [1 ]
Maru, Y [1 ]
机构：
[1] Tokyo Womens Med Univ, Sch Med, Dept Pharmacol, Tokyo 1628666, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2005年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：90P / 90P
页数：1
相关论文
共 50 条
  • [1] CRKL binding to BCR-ABL and BCR-ABL transformation
    Kolibaba, KS
    Bhat, A
    Heaney, C
    Oda, T
    Druker, BJ
    LEUKEMIA & LYMPHOMA, 1999, 33 (1-2) : 119 - 126
  • [2] ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity
    Upshaw, Jenica N.
    Travers, Richard
    Jaffe, Iris Z.
    JACC: CARDIOONCOLOGY, 2022, 4 (03): : 384 - 386
  • [3] Targeting of BCR-ABL: Lessons learned from BCR-ABL inhibition
    Lin, X.
    Qureshi, M. Z.
    Attar, R.
    Khalid, S.
    Tahir, F.
    Yaqub, A.
    Aslam, A.
    Yaylim, I.
    de Carlos Back, L. K.
    Farooqi, A. A.
    Ismail, M.
    CELLULAR AND MOLECULAR BIOLOGY, 2016, 62 (12) : 129 - 137
  • [4] Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation
    Heaney, C
    Kolibaba, K
    Bhat, A
    Oda, T
    Ohno, S
    Fanning, S
    Druker, BJ
    BLOOD, 1997, 89 (01) : 297 - 306
  • [5] Biology of BCR-ABL
    Chopra, R
    Pu, QQ
    Elefanty, AG
    BLOOD REVIEWS, 1999, 13 (04) : 211 - 229
  • [6] Research and Development of a Novel Process for Nilotinib: A Bcr-Abl Inhibitor
    Amala, K.
    Rao, A. K. S. Bhujanga
    Sreenivas, R.
    Dubey, P. K.
    ASIAN JOURNAL OF CHEMISTRY, 2013, 25 (08) : 4599 - 4602
  • [7] Nilotinib -: Bcr-Abl kinase inhibitor apoptosis inducer oncolytic
    Davies, S. L.
    Bolos, J.
    Serradell, N.
    Bayes, M.
    DRUGS OF THE FUTURE, 2007, 32 (01) : 17 - 25
  • [8] Is another Bcr-Abl inhibitor needed for chronic myelogenous leukemia?
    Sausville, EA
    CLINICAL CANCER RESEARCH, 2003, 9 (04) : 1233 - 1234
  • [9] Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib
    Tanaka, C.
    Yin, O. Q. P.
    Sethuraman, V.
    Smith, T.
    Wang, X.
    Grouss, K.
    Kantarjian, H.
    Giles, F.
    Ottmann, O. G.
    Galitz, L.
    Schran, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (02) : 197 - 203
  • [10] MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia
    Giles, F. J.
    Swords, R. T.
    Nagler, A.
    Hochhaus, A.
    Ottmann, O. G.
    Rizzieri, D. A.
    Talpaz, M.
    Clark, J.
    Watson, P.
    Xiao, A.
    Zhao, B.
    Bergstrom, D.
    Le Coutre, P. D.
    Freedman, S. J.
    Cortes, J. E.
    LEUKEMIA, 2013, 27 (01) : 113 - 117
12345